
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is projected to have a total market value of $837M with a 12-month price objective of $9 per share. This is based on a discounted cash flow approach with a 10% discount rate and a 1.0% terminal growth rate. The company has a favorable outlook with a 60% probability of approval for its lead assets and a 35% probability of approval for its other pipeline candidates. However, there are risks including negative clinical results, delays in advancing candidates, failure to achieve favorable results, regulatory approval challenges, competition, and long-term dilution risk.
Bears say
Caribou Biosciences is facing a negative outlook due to its heavy reliance on one main product, Vispacabtagene regedleucel, and lack of diversification. Additionally, the company has a high level of debt, with a current ratio of 2.2, which could put strain on its financial stability in the future. The change in fair value of the MSKCC payment liability also adds uncertainty to the company's financial situation.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares